Krystal Biotech (KRYS) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a report published on Tuesday morning. They currently have $28.00 target price on the stock.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
KRYS has been the subject of several other reports. Cantor Fitzgerald restated a buy rating and issued a $35.00 price target on shares of Krystal Biotech in a research note on Monday, October 15th. Cowen initiated coverage on Krystal Biotech in a research note on Wednesday, December 12th. They issued an outperform rating for the company. HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Krystal Biotech in a research note on Monday, November 5th. William Blair restated a buy rating on shares of Krystal Biotech in a research note on Monday, November 5th. Finally, ValuEngine upgraded Krystal Biotech from a hold rating to a buy rating in a research report on Friday, September 21st. Eight investment analysts have rated the stock with a buy rating, Krystal Biotech currently has an average rating of Buy and a consensus price target of $33.40.
Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 5th. The company reported ($0.26) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.26). As a group, equities research analysts forecast that Krystal Biotech will post -0.95 EPS for the current year.
In other news, insider Krish S. Krishnan bought 25,000 shares of the stock in a transaction on Thursday, October 18th. The stock was acquired at an average price of $20.00 per share, with a total value of $500,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 45.80% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of KRYS. BlackRock Inc. grew its stake in Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares during the period. Acadian Asset Management LLC grew its stake in Krystal Biotech by 68.5% during the third quarter. Acadian Asset Management LLC now owns 20,558 shares of the company’s stock worth $361,000 after purchasing an additional 8,356 shares during the period. P.A.W. Capital Corp bought a new position in Krystal Biotech in the third quarter worth approximately $527,000. JPMorgan Chase & Co. boosted its holdings in Krystal Biotech by 69.0% in the third quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after acquiring an additional 14,755 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Krystal Biotech in the third quarter worth approximately $891,000. 18.83% of the stock is owned by institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.